Jeremiah Li

Mr. Jeremiah Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Genome Research
Verified
Journal Article
Open access
PDF file
JLJeremiah Li
Jeremiah Li
CMChase A. Mazur
Chase A. Mazur
TBTomaz Berisa
Tomaz Berisa
JPJoseph K. Pickrell
Joseph K. Pickrell
Low-pass sequencing (sequencing a genome to an average depth less than 1× coverage) combined with genotype imputation has been proposed as an alternative to genotyping arrays for trait mapping and calculation of polygenic scores. To empirically assess the relative performance of these technologies for different applications, we performed low-pass sequencing (targeting coverage levels of 0.5× and 1×) and array genotyping (using the Illumina Global Screening Array [GSA]) on 120 DNA samples derived from African- and European-ancestry individuals that are part of the 1000 Genomes Project. We then imputed both the sequencing data and the genotyping array data to the 1000 Genomes Phase 3 haplotype reference panel using a leave-one-out design. We evaluated overall imputation accuracy from these different assays as well as overall power for GWAS from imputed data and computed polygenic risk scores for coronary artery disease and breast cancer using previously derived weights. We conclude that low-pass sequencing plus imputation, in addition to providing a substantial increase in statistical power for genome-wide association studies, provides increased accuracy for polygenic risk prediction at effective coverages of ∼0.5× and higher compared to the Illumina GSA.

5 November 2020 in Genes
Verified
Journal Article
Open access
PDF file
WSWarren Snelling
Warren Snelling
JHJesse L. Hoff
Jesse L. Hoff
JLJeremiah Li
Jeremiah Li
LKLarry A. Kuehn
Larry A. Kuehn
BKBrittney N. Keel
Brittney N. Keel
JPJoseph K. Pickrell
Joseph K. Pickrell
Decreasing costs are making low coverage sequencing with imputation to a comprehensive reference panel an attractive alternative to obtain functional variant genotypes that can increase the accuracy of genomic prediction. To assess the potential of low-pass sequencing, genomic sequence of 77 steers sequenced to >10X coverage was downsampled to 1X and imputed to a reference of 946 cattle representing multiple Bos taurus and Bos indicus-influenced breeds. Genotypes for nearly 60 million variants detected in the reference were imputed from the downsampled sequence. The imputed genotypes strongly agreed with the SNP array genotypes (r¯=0.99) and the genotypes called from the transcript sequence (r¯=0.97). Effects of BovineSNP50 and GGP-F250 variants on birth weight, postweaning gain, and marbling were solved without the steers’ phenotypes and genotypes, then applied to their genotypes, to predict the molecular breeding values (MBV). The steers’ MBV were similar when using imputed and array genotypes. Replacing array variants with functional sequence variants might allow more robust MBV. Imputation from low coverage sequence offers a viable, low-cost approach to obtain functional variant genotypes that could improve genomic prediction.

20 March 2021 in BMC Genomics
Verified
Journal Article
Open access
PDF file
KWKaja Wasik
Kaja Wasik
TBTomaz Berisa
Tomaz Berisa
JPJoseph K. Pickrell
Joseph K. Pickrell
JLJeremiah Li
Jeremiah Li
DFDana J. Fraser
Dana J. Fraser
CCCharles Cox
Charles Cox
Background: Low pass sequencing has been proposed as a cost-effective alternative to genotyping arrays to identify genetic variants that influence multifactorial traits in humans. For common diseases this typically has required both large sample sizes and comprehensive variant discovery. Genotyping arrays are also routinely used to perform pharmacogenetic (PGx) experiments where sample sizes are likely to be significantly smaller, but clinically relevant effect sizes likely to be larger.Results: To assess how low pass sequencing would compare to array based genotyping for PGx we compared a low-pass assay (in which 1x coverage or less of a target genome is sequenced) along with software for genotype imputation to standard approaches. We sequenced 79 individuals to 1x genome coverage and genotyped the same samples on the Affymetrix Axiom Biobank Precision Medicine Research Array (PMRA). We then down-sampled the sequencing data to 0.8x, 0.6x, and 0.4x coverage, and performed imputation. Both the genotype data and the sequencing data were further used to impute human leukocyte antigen (HLA) genotypes for all samples. We compared the sequencing data and the genotyping array data in terms of four metrics: overall concordance, concordance at single nucleotide polymorphisms in pharmacogenetics-related genes, concordance in imputed HLA genotypes, and imputation r2. Overall concordance between the two assays ranged from 98.2% (for 0.4x coverage sequencing) to 99.2% (for 1x coverage sequencing), with qualitatively similar numbers for the subsets of variants most important in pharmacogenetics. At common single nucleotide polymorphisms (SNPs), the mean imputation r2from the genotyping array was 0.90, which was comparable to the imputation r2from 0.4x coverage sequencing, while the mean imputation r2from 1x sequencing data was 0.96.Conclusions: These results indicate that low-pass sequencing to a depth above 0.4x coverage attains higher power for association studies when compared to the PMRA and should be considered as a competitive alternative to genotyping arrays for trait mapping in pharmacogenetics.

1 December 2023 in G3: Genes, Genomes, Genetics
Verified
Journal Article
Open access
PDF file
JLJeremiah Li
Jeremiah Li
KFKarrah Findley
Karrah Findley
JPJoseph K Pickrell
Joseph K Pickrell
KBKelly Blease
Kelly Blease
JZJunhua Zhao
Junhua Zhao
SKSemyon Kruglyak
Semyon Kruglyak
Low-pass sequencing with genotype imputation has been adopted as a cost-effective method for genotyping. The most widely used method of short-read sequencing uses sequencing by synthesis (SBS). Here we perform a study of a novel sequencing technology—avidity sequencing. In this short note, we compare the performance of imputation from low-pass libraries sequenced on an Element AVITI system (which utilizes avidity sequencing) to those sequenced on an Illumina NovaSeq 6000 (which utilizes SBS) with an SP flow cell for the same set of biological samples across a range of genetic ancestries. We observed dramatically lower optical duplication rates in the data deriving from the AVITI system compared to the NovaSeq 6000, resulting in higher effective coverage given a fixed number of sequenced bases, and comparable imputation accuracy performance between sequencing chemistries across ancestries. This study demonstrates that avidity sequencing is a viable alternative to the standard SBS chemistries for applications involving low-pass sequencing plus imputation.

30 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJeremiah Li
Jeremiah Li
CMChase A. Mazur
Chase A. Mazur
TBTomaz Berisa
Tomaz Berisa
JPJoseph K. Pickrell
Joseph K. Pickrell
Low-pass sequencing (sequencing a genome to an average depth less than 1x coverage) combined with genotype imputation has been proposed as an alternative to genotyping arrays for trait mapping and calculation of polygenic scores; however, the current literature is largely limited to simulation- and downsampling-based approaches. To empirically assess the relative performance of these technologies for different applications, we performed low-pass sequencing (targeting coverage levels of 0.5x and 1x) and array genotyping (using the Illumina Global Screening Array) on 120 DNA samples derived from African and European-ancestry individuals that are part of the 1000 Genomes Project. We then imputed both the sequencing data and the genotyping array data to the 1000 Genomes Phase 3 haplotype reference panel using a leave-one-out design. First, we evaluated overall imputation accuracy from these different assays as measured by genotype concordance; we introduce the concept of effective coverage that accounts for evenness of sequencing and show that this metric is a better predictor of imputation accuracy than nominal mapped coverage for low-pass sequencing data. Next, we evaluated overall power for genome-wide association studies (GWAS) as measured by the squared correlation between imputed and true genotypes. In the African individuals, at common variants (>5% minor allele frequency), imputation r2 averaged 0.83 for the array data and ranged from 0.89 to 0.95 for the low-pass sequencing data, corresponding to an effective 7-15% increase in GWAS discovery power. For the same variants in the European individuals, imputation r2 averaged 0.91 for the array data and ranged from 0.92-0.96 for the low-pass sequencing data, corresponding to an effective 1-6% increase in GWAS discovery power. Finally, we computed polygenic risk scores for breast cancer and coronary artery disease from the different assays. We observed consistently lower measurement error for risk scores computed from low-pass sequencing data above an effective coverage of ~0.5x. The mean squared error of the array-based estimates was three to four times that of the estimates from samples sequenced at an effective coverage of ~1.2x for coronary artery disease, with qualitatively similar results for breast cancer. We conclude that low-pass sequencing plus imputation, in addition to providing a substantial increase in statistical power for genome wide association studies, provides increased accuracy for polygenic risk prediction at effective coverages of ~0.5x and higher.

8 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
KWKaja Wasik
Kaja Wasik
TBTomaz Berisa
Tomaz Berisa
JPJoseph K. Pickrell
Joseph K. Pickrell
JLJeremiah Li
Jeremiah Li
DFDana J. Fraser
Dana J. Fraser
CCCharles Cox
Charles Cox
Low pass sequencing has been proposed as a cost-effective alternative to genotyping arrays to identify genetic variants that influence multifactorial traits in humans. For common diseases this typically has required both large sample sizes and comprehensive variant discovery. Genotyping arrays are also routinely used to perform pharmacogenetic (PGx) experiments where sample sizes are likely to be significantly smaller, but clinically relevant effect sizes likely to be larger. To assess how low pass sequencing would compare to array based genotyping for PGx we compared a low-pass assay (in which 1× coverage or less of a target genome is sequenced) along with software for genotype imputation to standard approaches. We sequenced 79 individuals to 1× genome coverage and genotyped the same samples on the Affymetrix Axiom Biobank Precision Medicine Research Array (PMRA). We then down-sampled the sequencing data to 0.8×, 0.6×, and 0.4× coverage, and performed imputation. Both the genotype data and the sequencing data were further used to impute human leukocyte antigen (HLA) genotypes for all samples. We compared the sequencing data and the genotyping array data in terms of four metrics: overall concordance, concordance at single nucleotide polymorphisms in pharmacogenetics-related genes, concordance in imputed HLA genotypes, and imputation r 2 . Overall concordance between the two assays ranged from 98.2% (for 0.4× coverage sequencing) to 99.2% (for 1× coverage sequencing), with qualitatively similar numbers for the subsets of variants most important in pharmacogenetics. At common single nucleotide polymorphisms (SNPs), the mean imputation r 2 from the genotyping array was 90%, which was comparable to the imputation r 2 from 0.4× coverage sequencing, while the mean imputation r 2 from 1× sequencing data was 96%. These results indicate that low-pass sequencing to a depth above 0.4× coverage attains higher power for trait mapping when compared to the PMRA.